Capricor Therapeutics Advances Clinical Development Program in Duchenne Muscular Dystrophy with Naming of Principal Investigator

Tuesday, September 26, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Internationally Recognized Expert Craig McDonald, M.D. to Lead Upcoming HOPE-2 Clinical Trial of CAP-1002



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook